First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Aims: A nationwide study to prospectively validate
1. The complete histological and molecular remission rate for antibiotics as 1st-line
therapy for early-stage Hp-positive gastric pure (de novo) DLBCL
2. The durability of complete histological remission after antibiotics
3. The usefulness of pattern of NF-kB, BCL10, BAFF, and CagA by IHC staining in
prospectively predicting the Hp-dependence of gastric pure (de novo) DLBCL
4. The frequency of t(11;18)(q21;q21) translocation in gastric pure (de novo) DLBCL in
Taiwan.
5. The association between the CYP2C18/CYP2C19 genetic polymorphisms and eradication of Hp
infection after antibiotics.
Phase:
Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital Changhua Christian Hospital China Medical University Hospital Kaohsiung Medical University Mackay Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital Taichung Veterans General Hospital